Summary Interaction of the SARS-CoV-2 Spike receptor binding domain (RBD) with the receptor ACE2 on host cells is essential for viral entry. RBD is the dominant target for neutralizing antibodies, and several neutralizing epitopes on RBD have been molecularly characterized. Analysis of circulating SARS-CoV-2 variants has revealed mutations arising in the RBD, N-terminal domain (NTD) and S2 subunits of Spike. To understand how these mutations affect Spike antigenicity, we isolated and characterized >100 monoclonal antibodies targeting epitopes on RBD, NTD, and S2 from SARS-CoV-2-infected individuals. Approximately 45% showed neutralizing activity, of which ∼20% were NTD specific. NTD-specific antibodies formed two distinct groups: the first was highly potent against infectious virus, whereas the second was less potent and displayed glycan-dependant neutralization activity. Mutations present in B.1.1.7 Spike frequently conferred neutralization resistance to NTD-specific antibodies. This work demonstrates that neutralizing antibodies targeting subdominant epitopes should be considered when investigating antigenic drift in emerging variants. Graphical abstract Highlights • Potent nAbs were isolated from an asymptomatic donor with low plasma neutralization • RBD-specific nAbs target epitopes overlapping with known RBD antibody classes • NTD mutations in B.1.1.7 Spike confer neutralization resistance to NTD-specific nAbs • Most RBD-specific nAbs retain potent neutralization of the B.1.1.7 variant The impact of mutations arising in SARS-CoV-2 Spike on antigenicity is still not known. Graham et al. isolate potent neutralizing monoclonal antibodies from individuals experiencing a range of COVID-19 disease severity that target RBD, NTD, and non-S1 epitopes. The B.1.1.7 variant of concern was most resistant to NTD-specific nAbs whereas RBD-specific nAbs retained potent neutralization.
【저자키워드】 SARS-CoV-2, antibody, neutralization, Immune escape, variant of concern, neutralizing epitope, B.1.1.7, 【초록키워드】 neutralizing antibody, antibodies, Mutation, Neutralizing antibodies, spike, disease severity, monoclonal antibody, variant, monoclonal antibodies, viral entry, variants, Receptor binding domain, COVID-19 disease, Epitopes, Neutralizing activity, B.1.1.7 variant, Viral, Asymptomatic, SARS-CoV-2 variants, B.1.1.7, RBD, plasma, NTD, antigenicity, epitope, potent, S2 subunit, neutralizing monoclonal antibodies, glycan, neutralizing monoclonal antibody, NAb, Donor, specific antibodies, SARS-CoV-2 spike, N-terminal domain, antigenic drift, Infectious virus, host cells, host cell, overlapping, Abstract, infected individuals, individual, NAbs, antigenic, COVID-19 disease severity, neutralization activity, receptor ACE2, SARS-CoV-2-infected individuals, MOST, circulating SARS-CoV-2 variants, neutralizing epitopes, dominant, Affect, characterized, arising, less, the RBD, retained, circulating SARS-CoV-2 variant, The B.1.1.7, the SARS-CoV-2, 【제목키워드】 spike, monoclonal antibody, Epitopes, epitope, dominant, recognizing, impacted,